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Abstract: The main function of the skin is to protect the body from the external environment.
The barrier function of the skin is mainly provided by the stratum corneum, which consists of
corneocytes bound with the corneodesmosomes and lamellar lipids. Skin barrier proteins like loricrin
and filaggrin also contribute to the skin barrier function. In various skin diseases, skin barrier
dysfunction is a common symptom, and skin irritants like detergents or surfactants could also
perturb skin barrier function. Many efforts have been made to develop strategies to improve skin
barrier function. Here, we investigated whether the microfluidized lysates of Lactobacillus rhamnosus
(LR), one of the most widely used probiotic species for various health benefits, may improve the
skin barrier function in a reconstructed human epidermis, Keraskin™. Application of LR lysate on
Keraskin™ increased the expression of tight junction proteins; claudin 1 and occludin as determined
by immunofluorescence analysis, and skin barrier proteins; loricrin and filaggrin as determined by
immunohistochemistry and immunofluorescence analysis and qPCR. Also, the cytotoxicity of a skin
irritant, sodium lauryl sulfate (SLS), was alleviated by the pretreatment of LR lysate. The skin barrier
protective effects of LR lysate could be further demonstrated by the attenuation of SLS-enhanced
dye-penetration. LR lysate also attenuated the destruction of desmosomes after SLS treatment.
Collectively, we demonstrated that LR lysate has protective effects on the skin barrier, which could
expand the utility of probiotics to skin-moisturization ingredients.
Keywords: probiotic; Lactobacillus rhamnosus; skin barrier; skin; reconstructed human epidermis model
1. Introduction
The skin is the largest organ of the body, which protects our body from the harmful environment
and helps to regulate our body temperature. The skin is composed of three layers, epidermis, dermis,
and the hypodermis. The outermost layer of the skin, the epidermis, is a multi-layered epithelial tissue,
and the barrier function of the skin is mainly provided by the stratum corneum. The stratum corneum
serves as a selective permeability barrier against infectious or toxic substances [1]. The stratum corneum
is composed of terminally differentiated keratinocytes called corneocytes, that are attached to each
other by corneodesmosomes and lamellar lipids. The structural organization of this barrier is also
referred as a ‘brick and mortar’ structure with the keratin microfibrils, filaggrin and cornified envelopes
forming the bricks and the lipids forming the mortar to seal together the cornified envelopes [2]. Also,
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tight-, gap-, and adherens junctions formed by desmosomes and proteins like loricrin or filaggrin
contribute to the protective skin barrier [3].
Although the barrier is self-maintaining and self-renewing, skin barrier dysfunction commonly
occurs in inflammatory skin disorders such as atopic dermatitis and psoriasis [3]. Disruption of the skin
barrier causes the collapse of moisture balance in the epidermis, allowing the penetration of allergens
or chemicals into the deeper layers of the skin, delaying remission or aggravating the diseases [4,5].
Topical glucocorticoids, a main dermatological pharmacotherapy, can worsen barrier dysfunction
and delay recovery [6]. Therefore, the use of skin barrier protective substances to maintain skin
hydration and restore barrier function constitutes a major adjunctive therapy for various dermatological
diseases [7].
Indeed, recent studies suggest that the complex response of epidermal cells to barrier disruption
is crucially involved in the pathogenesis of dermatological diseases. In this context, skin barrier
restoration may help the treatment of these dermatological conditions [4]. Topical application of
moisturizers formulated with epidermal barrier components like natural moisturization factor (NMF)
components [8], amino acids, and ceramides [9,10] could relieve dry skin condition and restore the
impaired skin barrier. In addition, emollients, antioxidants, and anti-inflammatory agents [11] are also
used for the skin barrier reestablishment [12]. However, still, many efforts are being made to discover
novel strategies to recover skin barrier dysfunction.
Probiotics are live microorganisms used for various health benefits on the host. Traditionally,
most probiotics are developed as foods or dietary supplements, targeting benefits on the intestine [13].
However, recent studies have shown that probiotics can have favorable effects on heart, liver, lung,
and even on mental health [14] as well. There is also escalating interest in the topical application
of probiotics for skin health. Bacterial strains that are adherent to the human skin have been
studied to identify probiotics [15]. Lactobacillus rhamnosus (LR), one of the widely used probiotic
strains, enhances intestinal barrier function, and help to prevent intestinal problems. LR exhibits
the epithelial barrier protection effect against enterotoxigenic Escherichia coli (ETEC) in the porcine
intestinal epithelial J2 cells. LR promotes TLR2/Akt activation, which increases tight junction integrity
and thus enhancing the barrier function and restricting pathogen invasion [16]. Topically applied LR
increased re-epithelization in keratinocyte scratch assays by promoting migration, which is involved in
the wound healing pathway [17]. Also, there is a report that L. rhamnosus GG increases tight-junction
function [18].
However, the effects of topically applied LR on skin barrier function have not been reported,
to our knowledge. Here, we investigated whether the microfluidized lysates of LR may improve
the skin barrier function in a 3D reconstructed human epidermis, Keraskin™ [19,20]. Following
the topical treatment of LR, epidermal structural components of barrier function were investigated
using immunohistochemistry, immunofluorescence staining, transmission electron microscopy, and
qPCR for epidermal differentiation markers. Protective effects on barrier function were evaluated
through measuring cytotoxicity and permeability in the presence or absence of a model irritant, sodium
lauryl sulfate.
2. Results
2.1. Topical Treatment of LR Lysate Increases Epidermal Differentiation Markers of a Reconstructed Human
Epidermis, Keraskin™
Lactobacillus rhamnosus (LR) lysate was prepared as described in the Methods section and was
characterized through examination under a microscope (Figure 1a). LR lysate was topically applied to
KeraskinTM every other day for 16 days. Then tissues were stained with H&E (Figure 1b). Sixteen
days of culture resulted in excessive generation of the stratum corneum. However, it is evident that LR
treated tissues have a more ordered and denser stratum corneum when compared to the control.
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Figure 1. Lysates of Lactobacillus rhamnosus (LR) and its effect on KeraskinTM. (a) Microscopic images 
of LR lysate before and after crushing. (b) Histology of H&E stained KeraskinTM after LR lysate 
treatment. LR lysate was topically applied to KeraskinTM every other day 8 times. Control; PBS. 
To further analyze the effects of LR on the epidermis, the treated tissues underwent 
immunofluorescence (IF) staining with antibodies against target junction proteins, claudin1, and 
occludin. IF images show that both tight junction molecules were increased in LR-treated 
KeraskinTM (Figure 2). 
 
Figure 2. Immunofluorescence images of LR treated KeraskinTM with antibodies against tight junction 
proteins. Claudin1 (upper red) and occludin (lower red) are stained and DAPI (blue) was used for 
nuclear staining. 
To further analyze the effects of LR on epidermal differentiation, the treated tissues underwent 
immunohistochemistry with antibodies against cytokeratin 5 (K5), 1 (K1), 10 (K10), loricrin (LOR) 
and filaggrin (FLG). As shown in Figure 3a and in the scoring of intensity (1 to 3) for each layer of the 
epidermis (Table 1), LR-treated tissues showed that K5 and K1 advanced into the upper layer of the 
epidermis; granular layer (GL) and cornified layer (CL), and the intensity increased while control 
tissues showed K5 and K1 expression limited within the basal layer. In the case of loricrin and 
filaggrin, there was no significant difference in the localization, but the intensity increased. There was 
no evident difference in the expression of K10. This pattern was further confirmed with 
immunofluorescence analysis (Figure 3b).  
Figure 1. Lysates of Lactobacillus rhamnosus (LR) and its effect on KeraskinTM. (a) Microscopic images of
LR lysate before and after crushing. (b) Histology of H&E stained KeraskinTM after LR lysate treatment.
LR lysate was topically applied to KeraskinTM every other day 8 times. Control; PBS.
To further analyze the effects of LR on the epidermis, the treated tissues underwent
immunofluorescence (IF) staining with antibodies against target junction proteins, claudin1, and
occludin. IF images show that both tight junction molecules were increased in LR-treated KeraskinTM
(Figure 2).
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Fig re 2. I nofl orescence i ages of treated eraskinTM ith antibo ies against tight j nction
proteins. laudin1 (upper red) and occludin (lo er red) are stained and PI (blue) as used for
nucl ar staining.
To further analyze the effects of LR on epidermal differentiation, the treated tissues underwent
immunohistochemistry with antibodies against cytokeratin 5 (K5), 1 (K1), 10 (K10), loricrin (LOR)
and filaggrin (FLG). As shown in Figure 3 and in th scoring of intensity (1 to 3) for each layer of
the epidermis (Table 1), LR-treated tissues showed that K5 and K1 advanced into the upper layer of
the epidermis; granular layer (GL) and cornified layer (CL), and the i t nsity increased whil c ntrol
tissu s showed K5 and K1 expression limited within the bas l layer. I the case of loricrin and filaggrin,
there was no signific t differ nce in the localization, but t intensity increased. There was no evident
difference in the expression of K10. This pattern was further confirmed with immunofluor scence
analysis (Figure 3b).
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Figure 3. Immunohistochemical and immunofluorescence images of KeraskinTM treated with LR 
lysate. (a) Immunohistochemical images of KeraskinTM with antibodies against cytokeratin 5 (K5), 1 
(K1), 10 (K10), loricrin (LOR) and filaggrin (FLG). LR lysate was topically applied to KeraskinTM every 
other day for 16 days. (b) Immunofluorescence images of KeraskinTM. DAPI (blue) was used for 
nuclear staining and red fluorescent indicated lineage markers. 
Table 1. The localization and intensity score of immunohistochemistry analysis of epidermal 
differentiation markers. 
Target Protein Test Chemical Localization Score (1–3) 
K5 (Cytokeratin5) Control BL, SL 1 LR BL, SL, GL, CL 3 
K1 (Cytokeratin1) Control BL, SL 2 LR BL, SL, GL, CL 3 
K10 (Cytokeratin10) Control SL, GL 3 
LR SL, GL 3 
LOR (Loricrin) Control SL, GL, CL 2 
LR SL, GL, CL 3 
FLG (Filaggrin) Control GL, CL 2 
LR BL, GL, CL 3 
2.2. LR Lysate Increases the Expression of Skin Barrier Proteins, Loricrin and Filaggrin in KeraskinTM 
To confirm IHC and IF data (Figure 3) and investigate whether LR could promote epidermal 
differentiation indeed, mRNA levels of loricrin and filaggrin that are major proteins for the formation 
of the epidermal barrier were evaluated using qPCR. LR lysate was topically applied to KeraskinTM 
for 2 days and mRNA was isolated as described in the Methods section and qPCR was conducted. 
As a result, LR-treatment significantly increased the expression of loricrin and filaggrin (by about 
60% and 40%, respectively, Figure 4), thus confirming the IHC results. 
Figure 3. Immunohistochemical and immunofluorescence images of KeraskinTM treated with LR lysate.
(a) Immunohistochemical images of KeraskinTM with antibodies against cytokeratin 5 (K5), 1 ( 1),
10 (K10), loricrin (LOR) and filaggrin (FLG). LR lysate was topically a plied to KeraskinTM every other
day for 16 days. (b) Immunofluorescence images of KeraskinTM. DAPI (blue) was used for nuclear
staining and red fluorescent indicated lineage markers.
Table 1. The localization and intensity score of immunohistochemistry analysis of epidermal
differentiation markers.
Target Protein Test Chemical Localization Score (1–3)
K5 (Cytokeratin5) Control BL, SL 1
LR BL, SL, GL, CL 3
K1 (Cytokeratin1) Control BL, SL 2
LR BL, SL, GL, CL 3
K10 (Cytokeratin10) Control SL, GL 3
LR SL, GL 3
LOR (Loricrin) Control SL, GL, CL 2
LR SL, GL, CL 3
FLG (Filaggrin) Control GL, CL 2
LR BL, GL, CL 3
2.2. LR Lysate Increases the Expression of Skin Barrier Proteins, Loricrin and Filaggrin in KeraskinTM
To confirm IHC and IF data (Figure 3) and investigate whether LR could promote epidermal
differentiation indeed, mRNA levels of loricrin and filaggrin that are major proteins for the formation
of the epidermal barrier were evaluated using qPCR. LR lysate was topically applied to KeraskinTM
for 2 days and mRNA was isolated as described in the Methods section and qPCR was conducted.
As a result, LR-treatment significantly increased the expression of loricrin and filaggrin (by about 60%
and 40%, respectively, Figure 4), thus confirming the IHC results.
Int. J. Mol. Sci. 2019, 20, 4289 5 of 12Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 13 
 
 
Figure 4. Increases of loricrin and filaggrin expression in LR-treated KeraskinTM. mRNA expressions 
of loricrin and filaggrin were measured by qRT-PCR. LR lysate was topically applied to KeraskinTM 
for 2 days. Results are expressed as mean ± SEM of independent three tests. *** p < 0.001 compared 
with PBS-treated control. 
2.3. Topical Treatment of LR Lysate Attenuated Irritant-Induced Cytotoxicity in Keraskin™ 
Skin barrier protective effects can be examined by determining the protection of irritant-induced 
cell death [21]. LR lysate was applied to Keraskin™ and an irritant, SLS was treated at various 
concentrations. As a result, treatment of LR significantly attenuated SLS-induced cell death in 
Keraskin™ as measured by WST-1 assay (Figure 5a). To visualize the protection effects of LR, 
Keraskin™ tissues were stained with H&E (Figure 5b). Histologic images also showed that LR treated 
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of SLS, which was in line with Figure 1b. Especially, while SLS treatment resulted in the almost 
complete disappearance of stratum corneum, LR treated tissues showed stratum corneum remaining. 
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Figure 5. Attenuation of irritant-induced cytotoxicity by LR in KeraskinTM. Tissues were pretreated 
with LR for every other day 4 times and SLS was treated for 10 min. (a) Tissue viability was 
determined by the WST-1 assay. Results are expressed by the fold of control viability as mean ± SE of 
independent more than three tests and analyzed by two-way ANOVA. * p < 0.05 compared with PBS-
treated control. (b) H&E stained tissues after with PBS or SLS treatment were measured by the light 
microscopy. 
2.4. Topical Treatment of LR Lysate Reduced the Skin Penetration of Rhodamine B 
We further studied the skin barrier protection effect of LR through a skin penetration study. 
Rhodamine B, a fluorescent dye, was used to evaluate the permeability of the skin. Keraskin™ was 
treated with LR for 24 h and 0.02% rhodamine B was treated for 2 h. After fixation with OCT 
compound and cryosection, the permeability of rhodamine B was evaluated with a fluorescence 
Figure 4. Increases of loricrin and filaggrin expression in LR-treated KeraskinTM. mRNA expressions
of loricrin and filaggrin were measured by qRT-PCR. LR lysate was topically applied to KeraskinTM for
2 days. Results are expressed as mean ± SEM of independent three tests. *** p < 0.001 compared with
PBS-treated control.
2.3. Topical Treatment of LR Lysate Attenuated Irritant-Induced Cytotoxicity in Keraskin™
Skin barrier protective effects can be examined by determining the protection of irritant-induced
cell death [21]. LR lysate was applied to Keraskin™ and an irritant, SLS was treated at various
concentrations. As a result, treatment of LR significantly ttenuated -induced cell death in
Keraskin™ as measured by WST-1 assay (Figure 5a). To visualize the protection eff cts of LR,
Keraskin™ tissues were stained with H&E (Figure 5b). Histologic images also showed that LR treated
epidermal tissues had more i tact stratum corne m than the c ntrol both in the pres nce nd abs nce
of SLS, which was in line with Figure 1b. Especially, w ile SLS treatme t r sulted in the lmost
c mplete disappearance of stratum corneum, LR tre ted tissu s showed stratum corneum remaining.
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Figure 5. Attenuation of irritant-induced cytotoxicity by LR in KeraskinTM. Tissues were pretreated
with LR for every other day 4 times and SLS was treated for 10 min. (a) Tissue viability was determined
by the WST-1 assay. Results are expressed by the fold of control viability as mean ± SE of independent
more than three tests and analyzed by two-way ANOVA. * p < 0.05 compared with PBS-treated control.
(b) H&E stained tissues after with PBS or SLS treatment were measured by the light microscopy.
2.4. Topical Treatment of LR Lysate Reduced the Skin Penetration of Rhodamine B
We fu ther studied the skin barrier protection effect LR through a skin penetration study.
Rhodamine B, a fluorescent dye, was used to evaluate the permeability of the skin. Keraskin™ was
treated with LR for 24 h and 0.02% rhodamine B was treated for 2 h. After fixation with OCT compound
and cryosection, the p rmeability of hodamine B was evaluated with a fluorescenc microscope.
As shown in Figure 6, fluorescence images confirmed hat the permeability of rhodamin B (red) was
reduc by treatment of LR both in the presence and absence of SLS.
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Desmosomes are intercellular junctions that provide mechanical strength to tissues. They are 
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function, we studied the effect of LR on desmosomes by the transmission electron microscopy (TEM) 
(Figure 7). When Keraskin™ was disrupted by SLS, the number of desmosomes was decreased in 
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Figure 6. Effects of LR on the skin pen tration of r ine B. Permeability of rhodamine B was
evaluated after 24 h treatment of LR with or without SLS pretreatment. The fluorescent images
represented rhodamine B (red), DAPI staining (blue).
2.5. LR Lysate Protects the Desmosome Degradation in Keraskin
Desmosomes are intercellular junctions that provide mechanical strength to tissues. They are
abundant in epithelial tissues. As desmosomes are one of the essential factors of the skin barrier
function, we studied the effect of LR on desmosomes by the transmission electron microscopy (TEM)
(Figure 7). When Keraskin™ was disrupted by SLS, the number of desmosomes was decreased in both
control nd LR treated groups but LR -treated Keraskin™ showed that desmosomes were damaged
less by SLS and more preserved than the control groups.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 13 
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3. Discussion
Here, we demonstrated that the lysates of Lactobacillus rhamnosus (LR), one of the most widely used
probiotic strains for various health benefits, can improve the skin barrier function using a reconstructed
human epidermis model, Keraskin™. Application of LR lysate on Keraskin™ increased the expression
of target junction proteins, claudin1 and occludin as seen in immunofluorescence images and the
expression of skin barrier proteins, loricrin and filaggrin at both protein and mRNA levels. Moreover,
the beneficial effects of LR lysate on the skin barrier function could be demonstrated by the attenuation
of the SLS-induced cytotoxicity and skin permeability in Keraskin™. Application of LR lysate also
attenuated the destruction of desmosomes by SLS.
Keratins form the intermediate filaments which become crosslinked as a cytoskeleton for the
cornified envelope, contributing to the stability of the epidermal barrier. The mutations of the keratins
cause incomplete intermediate filaments and disturbed barrier function [22]. One of the late epidermal
differentiation proteins, filaggrin aggregates the keratin filaments. Many studies demonstrated that the
loss of function in filaggrin causes the impaired formation of the epidermis and affect the skin barrier
function [23,24]. Loricrin is a major component of the cornified envelope and binds with filaggrin
for the formation of the cornified envelope and plays a key role in the skin barrier function [22].
Immunohistochemical images showed that the intensity of cytokeratins 5 and 1 increased and found at
the upper layer of the epidermis of LR-treated tissues and the intensity of loricrin and filaggrin also
increased, reflecting that LR may promote epidermal differentiation. This was confirmed through
qPCR analysis of loricrin and filaggrin. This indicates that the promotion of epidermal differentiation
by LR lysate may have increased barrier function through strengthening the stratum corneum, which
could be observed with H&E stained tissues.
SLS is an anionic surfactant widely used in various skincare products like soaps and shampoos.
SLS causes skin damages through disrupting stratum corneum integrity. We could also observe that
the stratum corneum of KeraskinTM was severely damaged by SLS. In addition, it is known that SLS
alters the expression pattern of keratinocyte differentiation markers [25]. We demonstrated that LR
treatment causes the increased expression of skin barrier proteins at both protein and mRNA levels.
So, it is highly likely that LR could enhance the stability and impermeability of the stratum corneum
in the presence of SLS though strengthening the stratum corneum, as shown in the histology and
permeation study.
Akt activation in keratinocytes promotes epidermal cell differentiation with the increased
expression levels of loricrin and filaggrin [26]. Akt activity is also essential for the barrier, especially in
the formation of the cornified envelope during the late and terminal differentiation [27]. Akt pathway
is generally activated by several extracellular signals such as growth factor, cytokines through
phosphoinositide 3-kinase (PI3K)-dependent signaling pathway. Especially, Toll-like receptor 2 (TLR2)
is the pattern recognition receptor expressed beneath the stratum corneum and serves to recognize the
presence of bacteria. Recently, TLR2 activation resulted in the activation of the PI3K/Akt pathway and
has been shown to enhance epithelial barrier function. It is demonstrated that L. rhamnosus promotes
TLR2/Akt activation in response to bacterial infection, thus protecting cells by maintaining the epithelial
barrier and promoting intestinal epithelial cell activation against an enterotoxigenic Escherichia coli [16].
In addition, it has been known that bacterial peptidoglycan-induced activation of TLR2 enhances
expression of tight junction proteins such as claudins, occludin and ZO proteins thus resulting in
enhanced barrier function in keratinocytes [28]. However, it is also reported that LR-augmented tight
junction function is not mediated by TLR2 in human keratinocytes [18]. It is thought that topical LR
treatment on the skin is derived by different mechanisms from the gut and also application of whole
lysates could undergo multiple signaling pathways for barrier protection effects. Currently, further
studies are necessary for how LR enhances the skin barrier function.
We examined whether the lysates of LR can have skin barrier protective effects. It would be
interesting to examine whether the application of live L. rhamnosus can manifest skin barrier protective
effects. However, in cosmetics, products must not be contaminated with microorganisms including
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probiotic species. The FDA regulates that acceptable limits for total (not pathogenic) microorganisms
in cosmetics are 500 colony forming units (cfu) per gram in eye-area products and 1000 cfu/g for other
area products [29]. So at this moment, the use of live probiotic strains in cosmetic products must
overcome this hurdle while other biotherapeutic approaches beyond cosmetics are on-going with
live probiotics [30]. If this hurdle could be mitigated by the amendment of cosmetic regulation, new
cosmetics for skin moisturization may be possible.
In conclusion, our results support LR has a beneficial effect on the maintaining of skin barrier
function. We demonstrated novel skin barrier protection effects of employing a reconstructed human
epidermis model. Further studies will be required to elucidate the mechanism of the skin barrier
protection effect of LR. With additional researches, LR could be used for the skincare products as the
topical probiotics.
4. Materials and Methods
4.1. Materials and Reagents
Lactobacillus rhamnosus (LR) was cultivated in Lactobacilli MRS Broth medium (Difco Franklin
Lakes, NJ, USA) at 30 ◦C, pH 6.2 for 2 days in static conditions. LR culture medium contained
protease peptone No. 3 (10.0 g), beef extract (10.0 g), yeast extract (5.0 g), glucose (20.0 g),
sorbitan monooleate complex(Tween 80, 1.0 g), ammonium citrate (2.0 g), sodium acetate
(5.0 g), K2HPO4 (2.0 g), MgSO4·7H2O (0.1 g), MnSO4·4H2O (0.05 g). LR was harvested
and crushed with a microfluidizer (Microfluidics, Newton, MA, USA). Identity of LR was
confirmed with gene sequencing for 16s ribosomal RNA to be Lactobacillus rhamnosus strain. WST-1
(4-[3-(indophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) (Roche, Indianapolis,
IN, USA), phosphate-buffered saline (PBS), sodium lauryl sulfate (SLS), rhodamine B were purchased
from Sigma–Aldrich (St. Louis, MO, USA).
4.2. A Reconstructed Human Epidermis Model (Keraskin™)
A reconstructed human epidermis model (Keraskin™) [31] and Keraskin™ culture media were
purchased from Biosolution Co., Ltd. (Seoul, Korea). Keraskin™ was placed on a six-well plate filled
with 0.9 mL Keraskin™ culture media per well, and pre-incubated for 20–24 h at 37 ◦C in a humidified
atmosphere containing 5% CO2. After pre-incubation, tissues were treated with 40 µL of various
concentrations of LR diluted in PBS. After 48 h treatment, tissues were rinsed with PBS. LR was treated
four or eight times, and control tissues were treated with PBS and followed the same schedule. Culture
media was changed every 48 h. After four or eight times of treatment, tissues were treated with various
concentrations of SLS diluted in PBS for 10 min and then rinsed with PBS to perturb skin condition.
4.3. WST-1 Assay
Tissue viability was determined by WST-1 assay which gives less damage to skin tissues [32].
After incubation, WST-1 diluted in sterile PBS was treated 300 uL for each tissue and incubated for 3 h
at 37 ◦C in a 5% CO2 incubator. Then 200 µL of solutions were transferred into a 96-well plate and
absorbance was determined by microplate spectrophotometer at 450 nm (BioTek Instruments, Inc.,
Winooski, VT, USA).
4.4. Histological Analysis
For the histological examination, all samples were cut in 10 mm-width and fixed in 4%
phosphate-buffered formalin (PFA) for 24 h, as described previously [33]. Fixed samples were
paraffin-embedded and cut into 5-µm section using microtome (Leica, RM2235), followed by
hematoxylin-eosin staining. Briefly, the sections were stained with 0.1% Mayer’s hematoxylin
for 10 min and 0.5% eosin in 95% EtOH. After staining with hematoxylin and eosin, the washing
steps were immediately and sequentially proceeded as follows: dip in distilled H2O until eosin stops
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streaking, dip in 50% EtOH for 10 times, dip in 70% EtOH for 10 times, incubated in 95% EtOH for
30 sec and 100% EtOH for 1 min. Then, samples were covered with a mounting solution (Thermo
Scientific, 6769007) and examined under the light microscope (OLYMPUS, BX43).
4.5. Immunohistochemistry (IHC) and Immunofluorescence Staining (IF)
For immunohistochemistry, skin samples were cut in cut into 5-µm section and were sequentially
proceeded rehydration steps with descending graded series of ethanol. Next, pH 6.0 antigen retrieval
(DAKO, S1699, Santa Clara, CA, USA) was conducted using a high-pressure cooker for 15 min, followed
the cooling phase over 1 h until the solution was fully transparent. After two washes in PBS, sections
were incubated in 3% H2O2 for 30 min for blocking endogenous peroxidase. Another two washes in
PBS, sections were incubated with protein block (DAKO, X0909, Santa Clara, CA, USA) for 1–2 h at
room temperature in a humidity-controlled chamber. Primary antibodies were incubated overnight at
4 ◦C. Commercial primary antibodies were purchased and diluted as described below:
Anti-keratin1 (ab185628, 1:1k) anti-keratin5 (ab52635, 1:500), anti-keratin10 (ab76318, 1:3k),
anti-loricrin (ab24722, 1:500) anti-filaggrin (NBP1-87528, 1:250). After three washes in PBS, sections
were incubated in HRP-labeled anti-rabbit antibody (DAKO, K4003, Santa Clara, CA, USA) for
15 min at room temperature. For the development of HRP-labeled antibody on section, DAB (DAKO,
K3468, Santa Clara, CA, USA) was diluted and put it on each section for the identical time. Mayer′s
hematoxylin (DAKO, S3309, Santa Clara, CA, USA) was used for counterstaining.
For immunofluorescence staining, skin samples were processed by the same procedure as described
in the immunohistochemistry protocol until incubation of primary antibodies. Commercial primary
antibodies were purchased and diluted as described below:
Anti-keratin1 (ab185628, 1:1k) anti-keratin5 (ab52635, 1:500), anti-keratin10 (ab76318, 1:3k),
anti-loricrin (ab24722, 1:500) anti-filaggrin (NBP1-87528, 1:250), anti-Claudin1 (51-9000, 1:250)
anti-occludin (SC-133256, 1:500). After incubation of primary antibodies, samples were immediately
washed in PBS two times. Next, samples were incubated with Alexa-568 conjugated anti-rabbit or
anti-mouse (Jackson laboratory, Bar Harbor, ME, USA) for 1 h at room temperature. After three washes
with PBS, DAPI (Sigma, St. Louis, MO, USA) was used for nuclear staining. All immunofluorescence
images were captured by EVOS-FL (Thermo Scientific, Fremont, CA, USA).
4.6. RNA Preparation and Quantitative Real-Time PCR (qRT-PCR) for the Determination of mRNA
Expression
Total RNA was isolated from KeraskinTM by RNA extraction kit according to manufacturer′s
guidelines (Qiagen, Valencia, CA, USA) and a previous report [34]. Then isolated RNA was quantified
by spectrophotometer (NanoDrop spectrophotometer; Thermo Scientific, Fremont, CA, USA). Total
RNA was reverse transcribed into cDNA using RT master premix with oligo dT (Elpis Biotech
Inc., Seoul, Korea) then analyzed by qRT-PCR using an Applied Biosystems 7300 real-time PCR
System (Applied Biosystems, Waltham, MA, USA). The sequences of PCR primers were: for
loricrin 5′-CCAGACCCAGCAGAAGCAG-3′ (forward) and 5′-TGCCCCTGGAAAACACCTC-3′
(reverse), filaggrin 5′-GAGGGCACTGAAAGGCAAAA-3′ (forward) and 5′-CTTCCGTGCT
GAGAGTGTCT-3′ (reverse), β-actin 5′-GCAAAGACCTGTACGCCAAC-3′ (forward) and 5′-GATCTT
CATTGTGCTGGGTGC-3′ (reverse). Primers for human loricrin, filaggrin and β-actin were purchased
from Cosmo Genetech (Seoul, Korea). Cycling parameters were 50 ◦C for 2 min, 95 ◦C for 10 min,
40 cycles of 95 ◦C for 15 s, and 58 ◦C for 1 min. For the comparisons, mRNA levels of target genes
were normalized to the corresponding β-actin levels in the KeraskinTM and expressed as target gene
normalized to β-actin. Relative quantification was performed using the comparative ∆∆Ct method
according to the manufacturer′s instructions.
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4.7. Skin Penetration Study
Rhodamine B, a hydrophilic dye, was treated to evaluate the permeability of the skin as described
previously [35]. Keraskin™ was treated with LR for 24 h and rinsed with PBS. 0.02% rhodamine B
was treated for 2 h and gently washed with an autoclaved cotton swab. Then cultured tissues were
initially cut in 10 mm-width and immediately embedded in OCT compound (Sakura, 4583, Tokyo,
Japan) using dry ice. Embedded samples were cut into 5-µm width and incubated in room temperature
for 40–60 min. Samples were washed in 1X phosphate-buffered saline (PBS) two times for 3 min
respectively. After 2 washes, 1000 times diluted DAPI (Sigma, 4583, St. Louis, USA) in 1X PBS were
treated on slides which pre-marked by a pen (Enzo, ADI-950-233-0001) for 5 min, followed by three
washes in PBS. After then, samples were covered by mount solution (Thermo Scientific, 9990402,
Waltham, USA) and immunofluorescence images were captured by EVOS-FL.
4.8. Transmission Electron Microscopy (TEM)
Samples were incubated for 24 h in 2% Glutaraldehyde-Paraformaldehyde in 0.1 M PBS and
washing in 0.1 M phosphate buffer (PB). Then, samples were post-fixed with 1% OsO4 dissolved in
0.1 M PB for 2 h and dehydrated in an ascending graded series (50–100%) of ethanol and infiltrated
with propylene oxide. Specimens were embedded by Poly/Bed 812 kit (Polysciences). After pure fresh
resin embedding and polymerization at 65 ◦C vacuum oven (DOSASKA, TD-700) for 24 h, sections of
200–250 nm in thickness were initially cut and stained with toluidine blue (Sigma, T3260) for light
microscopy. 70-nm thin sections were double-stained with 6% uranyl acetate for 20 min and lead citrate
for contrast staining. Sections were cut by LEICA EM UC-7 with a diamond knife and transferred
onto copper and nickel grids. Desmosomes were examined under transmission electron microscopy
(JEM-1011, JEOL) at a voltage of 80 kV.
4.9. Statistical Analysis
Results are expressed as the mean ± standard error of the mean (S.E.M) of three or more
independent experiments. The statistical analyses were performed by Student’s t-test or two-way
ANOVA. p-value < 0.05 was considered statistically significant.
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Abbreviations
LR Lactobacillus rhamnosus
SLS Sodium lauryl sulfate
ETEC Enterotoxigenic Escherichia coli
K5 Cytokeratin 5
K1 Cytokeratin 1
K10 Cytokeratin 10
LOR Loricrin
FLG Filaggrin
BL Basal layer
SL Spinous layer
GL Granular layer
CL Cornified layer
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WST-1 4-[3-(indophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
PBS Phosphate-buffered saline
PFA Phosphate-buffered formalin
IHC Immunohistochemistry
IF Immunofluorescence staining
PB Phosphate buffer
TEM Transmission electron microscopy
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